Key Clinical Trial Terms
Clinical Trial Phase
The stages of testing a drug: Phase 1 (Safety and dosing), Phase 2 (Preliminary efficacy and dosing in patients), Phase 3 (Comparison to standard treatment in large groups), and Phase 4 (Long-term monitoring after approval).
NCT Number
A unique identification number assigned to each clinical trial (e.g., NCT01234567). It serves as the "ID card" for the study in global databases.
Recruiting
The status indicating that a clinical trial is currently open and looking for new participants to join.
Protocol
The detailed plan that describes how a clinical trial will be conducted, including treatment dosing, visit schedule, tests, and procedures. When doctors say "the protocol," they are referring to this plan.
Primary & Secondary Endpoints
What researchers are trying to achieve in the trial. A primary endpoint might be shrinking the tumor or stopping the disease, while secondary endpoints often look at the drug's safety or improvements in the patient's quality of life.
Principal Investigator (PI)
The lead doctor responsible for conducting and overseeing the clinical trial at a specific medical site.
Sponsor
The organization (pharmaceutical company, hospital, or agency) that initiates, manages, and finances the clinical trial.
Standard of Care (SOC)
The current best accepted treatment for the disease by the medical community. In many trials, the control group receives this standard treatment.
Line of Therapy
Many trials require a patient to have completed a "first" or "second" line of therapy. This refers to the main treatments the patient has already received for their disease, which directly affects their eligibility for a trial.
Biomarkers & Mutations
Terms like EGFR, BRCA, or protein expression. Many modern trials require a specific molecular profile of the tumor. Therefore, it's important for patients to ask their doctor for genetic sequencing to find trials tailored to their specific biology.
Inclusion Criteria
The rules that decide who can join a trial. "Inclusion criteria" are the things you must have (like a specific diagnosis).
Exclusion Criteria
"Exclusion criteria" are factors that disqualify someone (like certain past treatments or health conditions) to ensure patient safety.
Eligibility
The overall status of whether a patient fits the study protocol based on the inclusion and exclusion criteria.
Informed Consent
The detailed document and process where all the trial's risks and benefits are explained before joining. It is not a binding contract—the participant can choose to leave the trial at any time.
Washout Period
The required time that must pass between finishing a previous treatment and starting the experimental one, allowing the body to "clear" the old drug and prevent unwanted interactions.
Screening Phase
The initial period of a few weeks after you express interest, where you undergo blood tests, scans, and check-ups. This is done to safely confirm that you perfectly meet all the trial's requirements before you start receiving the treatment.
Randomization
The process of assigning patients to different groups in a trial. This is done by a computer program (like flipping a coin), not by the doctor, to prevent bias in the research.
Cohort
A group of participants in a clinical trial who share similar medical characteristics.
Crossover Design
A reassuring trial design where participants switch treatments during the study. For example, if you start in the control group and your disease progresses, you may be allowed to "cross over" and receive the new experimental drug.
Placebo (and Control Group)
The control group is the group to which the new treatment is compared. It's important to know that in oncology and many severe diseases, the control group rarely gets a "sugar pill" (placebo); instead, they receive the best standard treatment currently available.
Double-Blind
A study where neither the patient nor the doctor knows which specific treatment the patient is receiving during the trial. This is done to prevent any bias in the results. If a medical emergency happens, the information can be instantly revealed to ensure safety.
Open-Label
A clinical trial where both the doctor and the patient know exactly which treatment the patient is receiving (as opposed to a double-blind trial where this is hidden).
Progression-Free Survival (PFS)
A common goal measured in trials, especially in oncology. Despite the word "survival," it simply measures how long the treatment successfully keeps the disease stable, quiet, or from growing, even if the tumor doesn't disappear completely.
Performance Status (ECOG)
A score (0 to 5) measuring how well a patient can carry out daily activities. Most trials require an ECOG score of 0 or 1, meaning the patient is fully active or restricted in strenuous activity but can still walk and carry out light work. This is one of the most common reasons patients are found ineligible for trials.
Adverse Events (AE)
A medical term describing any health issue or side effect that occurs during the trial, even if it's not necessarily caused by the experimental treatment.
Compassionate Use (Expanded Access)
An option sometimes available for patients who don't meet the strict criteria of a clinical trial but urgently need treatment and may benefit from the experimental drug.
Basket Trial
A trial that tests a drug on patients with different types of cancer that share a common genetic mutation or biomarker. Instead of focusing on where the cancer is located, it focuses on what drives it genetically.
Natural History Study
An observational study that tracks how a disease progresses over time in patients, without testing any treatment. These studies are especially important in rare diseases, where being enrolled can put patients first in line for future treatment trials.
This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.